Company news
Cocrystal Pharma, Inc. (NASDAQ:COCP) news
Cocrystal Pharma, Inc. news releases on 6ix. Latest, Jan 6, 2022: Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19…
Press releases — page 3
Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205
January 5, 2022
Cocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual Conference
January 3, 2022
Cocrystal Pharma’s COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant
December 21, 2021
Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow
December 1, 2021
Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021
November 30, 2021
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development Programs and Milestones
November 14, 2021
Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses
November 7, 2021
Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment
October 31, 2021
Cocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021
October 20, 2021
Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021
October 13, 2021
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza
October 5, 2021
Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 6, 2021
Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates
August 15, 2021
Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants
July 28, 2021
Cocrystal Joins Russell Microcap® Index
June 27, 2021
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
June 22, 2021
Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants
June 13, 2021
Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox
May 27, 2021
Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
May 16, 2021
Cocrystal Pharma Announces Closing of $40 Million Bought Deal
May 6, 2021
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock
May 3, 2021
Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs
May 2, 2021
Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones
March 16, 2021
Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX
March 9, 2021
Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement
January 18, 2021
Cocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses
December 21, 2020
Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs
November 15, 2020
Cocrystal Pharma Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
October 1, 2020
Cocrystal Pharma Announces Closing of $17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchase Additional Shares
August 30, 2020
Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million
August 25, 2020
Cocrystal Pharma Announces $10.0 Million Bought Deal Offering
August 25, 2020
Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
August 5, 2020
Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal
August 3, 2020
Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
May 13, 2020
Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs
May 10, 2020
Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action
April 21, 2020
Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors
April 19, 2020
Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020
March 29, 2020
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market
March 10, 2020
Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market
March 8, 2020
Cocrystal Pharma Announces Plans to Advance Coronavirus Program
March 5, 2020
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
February 27, 2020
Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market
February 26, 2020
Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds
February 23, 2020
COCRYSTAL PHARMA, INC. ANNOUNCES CLOSING OF $2.2 MILLION REGISTERED DIRECT OFFERING
February 2, 2020
COCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING
January 28, 2020
Cocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 11, 2019
Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV
November 10, 2019
COCRYSTAL PHARMA, INC. PRICES $3,000,000 UNDERWRITTEN PUBLIC OFFERING
October 30, 2019
COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
October 29, 2019